The present situation and future of transplantation therapy for follicular lymphoma in the time of rituximab

VernacularTitle:利妥昔单抗时代滤泡性淋巴瘤移植治疗的现状及前景
Author: Xiaochen CHEN ; Depei WU
Publication Type:Journal Article
Keywords: Lymphoma,follicular; Hematopoietic stem cell transplantation; Rituximab; Therapy
From: Journal of Leukemia & Lymphoma 2013;22(6):335-338
CountryChina
Language:Chinese
Abstract: Follicular lymphoma (FL) is a subtype of B cell lymphoma,which derived from follicular germinal center.As the most common type of indolent lymphoma,the overall prognosis of FL is good.However,the prognosis of FL is heterogeneous.With the application of rituximab,the therapeutic effect and the prognosis of the disease is further improved.For the relapsed / refractory patients,especially who have received first-line chemotherapy with rituximab in the early,transplantation is an important choice.Compared with the previous conventional myeloablative conditioning regimen,reduced-intensity conditioning (RIC) effectively reduced the non-relapse mortality (NRM),extended the allogeneic transplantation recipients,but the high rate of relapse after transplantation is the main defect.The application of donor lymphocyte infusion after transplantation therapy not only can reduce the recurrence rate but also treat the disease relapse.In the future,the improvement of transplantation strategy and the application of new drugs may bring new ideas and opportunities for FL therapy.